Literature DB >> 16875671

FOXM1c is activated by cyclin E/Cdk2, cyclin A/Cdk2, and cyclin A/Cdk1, but repressed by GSK-3alpha.

Inken Wierstra1, Jürgen Alves.   

Abstract

Two different inhibitory domains, N-terminus and central domain, keep FOXM1c almost inactive despite its strong transactivation domain. Here, we demonstrate that cyclin E/Cdk2, cyclin A/Cdk2, and cyclin A/Cdk1 activate FOXM1c. Cyclin E/Cdk2 does not target its transactivation domain or its DNA-binding domain. Instead, its activating effect strictly depends on the presence of either the central domain or the N-terminus of FOXM1c and thus is completely lost if both inhibitory domains are deleted. Cyclin E/Cdk2 activates FOXM1c by releasing its transactivation domain from the repression by these two inhibitory domains. However, it does not directly increase the transactivation potential of the TAD. The DNA-binding is not affected by cyclin E/Cdk2, neither directly nor indirectly. These two activating effects of cyclin E/Cdk2 via central domain and N-terminus are additive. Cyclin A/Cdk2 and cyclin A/Cdk1 show similar characteristics. GSK-3alpha, another proliferation-associated kinase, represses FOXM1c.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16875671     DOI: 10.1016/j.bbrc.2006.07.008

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  13 in total

1.  An N-terminal inhibitory domain modulates activity of FoxM1 during cell cycle.

Authors:  H J Park; Z Wang; R H Costa; A Tyner; L F Lau; P Raychaudhuri
Journal:  Oncogene       Date:  2007-09-24       Impact factor: 9.867

2.  FOXM1c promotes pancreatic cancer epithelial-to-mesenchymal transition and metastasis via upregulation of expression of the urokinase plasminogen activator system.

Authors:  Chen Huang; Dacheng Xie; Jiujie Cui; Qi Li; Yong Gao; Keping Xie
Journal:  Clin Cancer Res       Date:  2014-01-22       Impact factor: 12.531

3.  Regulation of a transcription factor network by Cdk1 coordinates late cell cycle gene expression.

Authors:  Benjamin D Landry; Claudine E Mapa; Heather E Arsenault; Kristin E Poti; Jennifer A Benanti
Journal:  EMBO J       Date:  2014-04-08       Impact factor: 11.598

4.  Activation of FoxM1 during G2 requires cyclin A/Cdk-dependent relief of autorepression by the FoxM1 N-terminal domain.

Authors:  Jamila Laoukili; Monica Alvarez; Lars A T Meijer; Marie Stahl; Shabaz Mohammed; Livio Kleij; Albert J R Heck; René H Medema
Journal:  Mol Cell Biol       Date:  2008-02-19       Impact factor: 4.272

5.  FOXM1 is a transcriptional target of ERalpha and has a critical role in breast cancer endocrine sensitivity and resistance.

Authors:  J Millour; D Constantinidou; A V Stavropoulou; M S C Wilson; S S Myatt; J M-M Kwok; K Sivanandan; R C Coombes; R H Medema; J Hartman; A E Lykkesfeldt; E W-F Lam
Journal:  Oncogene       Date:  2010-03-08       Impact factor: 9.867

6.  Dysregulated expression of FOXM1 isoforms drives progression of pancreatic cancer.

Authors:  Xiangyu Kong; Lei Li; Zhaoshen Li; Xiangdong Le; Chen Huang; Zhiliang Jia; Jiujie Cui; Suyun Huang; Liwei Wang; Keping Xie
Journal:  Cancer Res       Date:  2013-04-18       Impact factor: 12.701

7.  Cdc2p controls the forkhead transcription factor Fkh2p by phosphorylation during sexual differentiation in fission yeast.

Authors:  Midori Shimada; Chisato Yamada-Namikawa; Yuko Murakami-Tonami; Takashi Yoshida; Makoto Nakanishi; Takeshi Urano; Hiroshi Murakami
Journal:  EMBO J       Date:  2007-12-06       Impact factor: 11.598

Review 8.  Quantitative model of eukaryotic Cdk control through the Forkhead CONTROLLER.

Authors:  Matteo Barberis
Journal:  NPJ Syst Biol Appl       Date:  2021-06-11

9.  Novel interactions between FOXM1 and CDC25A regulate the cell cycle.

Authors:  Con Sullivan; Youhong Liu; Jingjing Shen; Adam Curtis; Christina Newman; Janet M Hock; Xiong Li
Journal:  PLoS One       Date:  2012-12-11       Impact factor: 3.240

10.  Genome-wide mapping of FOXM1 binding reveals co-binding with estrogen receptor alpha in breast cancer cells.

Authors:  Deborah A Sanders; Caryn S Ross-Innes; Dario Beraldi; Jason S Carroll; Shankar Balasubramanian
Journal:  Genome Biol       Date:  2013-01-24       Impact factor: 13.583

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.